Decompensated Chronic Liver Disease (DCLD) with Hepatorenal Syndrome (HRS)

Definition

Pathophysiology

1. Splanchnic + systemic vasodilation - Portal hypertension triggers release of vasoactive mediators (nitric oxide, CO, glucagon, prostacyclin) causing progressive splanchnic arterial dilation. This reduces effective circulating blood volume.
2. Compensatory renal vasoconstriction - Activation of RAAS, SNS, and increased ADH secretion compensate initially but eventually cause intense renal arterial vasoconstriction and a marked fall in GFR. Drugs like ACEIs, ARBs, and NSAIDs can worsen this directly.
3. Cirrhotic cardiomyopathy (CCM) - Impaired cardiac function further worsens renal hypoperfusion and is increasingly recognized as a contributor.

Classification (Updated ICA/ADQI Terminology)

• Stage 1: Creatinine rise ≥0.3 mg/dL or ≥1.5-2x baseline
• Stage 2: Creatinine rise >2-3x baseline
• Stage 3: Creatinine rise >3x baseline OR ≥4 mg/dL with acute rise ≥0.3 mg/dL OR need for renal replacement therapy

Diagnosis

1. Stop diuretics
2. Albumin volume expansion - 1 g/kg/day for 48 hours (max 100 g/day) - no significant improvement in creatinine
3. Exclude other causes of AKI:
   • Pre-renal: GI bleed, over-diuresis, diarrhea
   • Intrinsic: acute tubular necrosis, acute interstitial nephritis, glomerulonephritis (check urine sediment, protein, casts)
   • Obstructive: renal US
   • Sepsis / SBP (diagnostic paracentesis in all admitted cirrhotics)
   • Nephrotoxins: NSAIDs, aminoglycosides, contrast
4. No sustained improvement after plasma expansion

Treatment

Pharmacological (First-line)

Supportive

• Stop all nephrotoxins (NSAIDs, aminoglycosides, ACEIs/ARBs, contrast)
• Treat precipitants aggressively (antibiotics for SBP/sepsis; blood transfusion for GI bleed)
• Restrict fluid only if severe hyponatremia; avoid excessive free water
• Renal replacement therapy (dialysis/CRRT) - as a bridge to transplant, not standalone therapy

Definitive

• Liver transplantation (LT) is the only curative option - renal function typically recovers post-LT
• For HRS-CKD: simultaneous liver-kidney transplant (SLKT) may be needed if renal dysfunction persists >12 weeks

Prevention

• IV albumin 1.5 g/kg at SBP diagnosis + 1 g/kg on day 3 - reduces HRS development from ~30% to ~10% in SBP
• Norfloxacin prophylaxis in patients with low-protein ascites (<1.5 g/dL) + advanced cirrhosis reduces HRS risk
• Albumin post large-volume paracentesis (6-8 g per liter removed) prevents circulatory dysfunction

Prognosis

• HRS-AKI untreated: median survival 2-4 weeks
• HRS-AKI with terlipressin: 30-day survival improves significantly if reversal achieved
• HRS-CKD: median survival ~6 months without transplant
• Post-LT: renal recovery occurs in most HRS patients who had functional (not organic) failure

Decompensated Chronic Liver Disease (DCLD)

Definition

Pathophysiology Overview

1. Splanchnic vasodilation (NO-mediated) → reduced effective circulating blood volume
2. RAAS + SNS activation → sodium and water retention → ascites
3. Progressive rise in portal pressure → varices → bleeding
4. Reduced hepatic clearance of gut-derived toxins → encephalopathy
5. Immune dysfunction + translocation of gut bacteria → SBP

Severity Scoring

Child-Turcotte-Pugh (CTP) Score (Range 5-15) - Goldman-Cecil Medicine

• Child A (5-6): Compensated
• Child B (7-9): Significant functional compromise
• Child C (10-15): Decompensated - high mortality

MELD-Na Score (Range 6-40)

• MELD(Na) = MELD + 1.32 × (137 - Na) - [0.033 × MELD × (137 - Na)]

Major Complications of DCLD

1. Ascites

• Most common decompensating event (7-10% per year in compensated cirrhosis)
• Develops from portal hypertension + RAAS activation + hypoalbuminaemia

• Sodium restriction (88 mEq/day = ~2 g/day)
• Diuretics: Spironolactone (100 mg/day, up to 400 mg) ± furosemide (40 mg/day, up to 160 mg) in 100:40 ratio
• Large-volume paracentesis (LVP) for tense/refractory ascites + albumin 6-8 g/L removed (prevents post-paracentesis circulatory dysfunction)
• TIPS (transjugular intrahepatic portosystemic shunt) for refractory ascites
• Refractory ascites: LVP every 2-4 weeks; TIPS if eligible; consider transplant listing

2. Variceal Hemorrhage

• Gastroesophageal varices present in ~50% of newly diagnosed cirrhosis; prevalence 40% (Child A) to 85% (Child C)
• Varices grow at 7-8%/year; large varices bleed at ~15%/year - Goldman-Cecil Medicine
• Predictors of bleeding: large varices, severe liver disease, red wale markings on endoscopy

• Non-selective beta-blockers (NSBB): propranolol, nadolol, or carvedilol
• Endoscopic variceal ligation (EVL) for medium/large varices or if NSBB contraindicated/not tolerated

1. ABC stabilization - avoid over-transfusion (target Hb 7-8 g/dL; restrictive strategy reduces rebleeding)
2. Vasoactive drugs (start immediately, before endoscopy): terlipressin, somatostatin, or octreotide for 3-5 days
3. Prophylactic antibiotics: IV ceftriaxone 1 g/day for 7 days (reduces SBP and improves survival)
4. Urgent endoscopy within 12 hours: EVL (preferred) or sclerotherapy
5. TIPS if endoscopic treatment fails (salvage TIPS)
6. Balloon tamponade (Sengstaken-Blakemore tube) as bridge only if bleeding uncontrolled

3. Spontaneous Bacterial Peritonitis (SBP)

• ~1/3 of admitted cirrhotics have bacterial infection; SBP is most common
• Most frequent organisms: gram-negative enterics (E. coli, Klebsiella); increasingly multidrug-resistant organisms due to antibiotic prophylaxis
• Diagnosis: ascitic fluid PMN count >250 cells/µL (even without positive culture)
• Positive culture in only 40-50% cases
• Diagnostic paracentesis should be done at ANY admission of a cirrhotic patient, regardless of reason - Goldman-Cecil Medicine

• IV ceftriaxone or cefotaxime 5-7 days
• IV albumin 1.5 g/kg at diagnosis + 1 g/kg on day 3 → reduces HRS and mortality
• Long-term antibiotic prophylaxis after SBP: norfloxacin 400 mg/day (or ciprofloxacin/trimethoprim-sulfamethoxazole as alternatives)

4. Hepatic Encephalopathy (HE)

• Neuropsychiatric syndrome from gut-derived toxins (esp. ammonia) bypassing the liver
• Ranges from minimal HE (detectable only on psychometric tests) to overt HE (confusion, asterixis, coma)
• Ammonia levels correlate poorly with grade; not reliable for diagnosis or monitoring (levels >150 µmol/L are however suggestive) - Goldman-Cecil Medicine
• Precipitants: GI bleed, infection, hyponatremia, constipation, over-diuresis, sedatives, renal failure

• Identify and treat precipitant
• Lactulose (titrate to 2-3 soft stools/day) - first-line; reduces intestinal ammonia
• Rifaximin 550 mg BD - adds to lactulose for prevention of recurrence; minimal systemic absorption
• Dietary protein: do NOT restrict protein (worsens sarcopenia); prefer BCAA-enriched or vegetable protein
• Zinc supplementation (often deficient in cirrhotics)

5. Hepatorenal Syndrome (HRS)

• Functional renal failure in ~10-30% of hospitalized cirrhotics (see detailed HRS discussion above)
• HRS-AKI (old Type 1): rapid progressive, median survival 2-4 weeks untreated
• HRS-CKD (old Type 2): slower, associated with refractory ascites

6. Hepatopulmonary Syndrome (HPS) & Portopulmonary Hypertension (PPH)

• HPS: Intrapulmonary vascular dilation → shunting → hypoxemia (PaO2 <80 mmHg or A-a gradient >15 mmHg + contrast echocardiography showing shunt); treated by LT
• PPH: Pulmonary arterial hypertension in portal hypertension context; mPAP >25 mmHg; managed with pulmonary vasodilators; severe PPH (mPAP >50) is a contraindication to LT

General Management Principles

Prognosis